Skip to content

Low Dialysate Temperature During SLED

Low Dialysate Temperature to Prevent Intradialytic Hypotension During SLED in AKI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03397992
Enrollment
38
Registered
2018-01-12
Start date
2017-01-16
Completion date
2017-04-22
Last updated
2018-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Intra-dialytic Hypotension

Brief summary

Objectives: This study is evaluating the hemodynamic effects of lowering the dialysate temperature in acute kidney injury (AKI) patients submitted to sustained low efficiency dialysis (SLED) in a single large center. Methods: Participants will be randomly assigned to two treatment groups. One group will be started treatment with low temperature (set point 5 on the machine which is around 35°C) for one treatment and then alternate between high and low temperatures for a maximum of 8 treatments. The other group will be started with high temperature (set point 9 on the machine which is around 37°C) for the first treatment then alternate between high and low temperatures for a maximum of 8 treatments. Each participants will need at least two treatments, one with each temperature to be included in the analysis. The investigators will be looking for the number of events during a SLED treatment. Events will be defined as drop in systolic blood pressure ≥ 20 mmHg or drop in mean arterial pressure (MAP) of ≥10 mmHg, requirement of resuscitation with IVF after initiation of SLED, initiation or increase requirement of vasoactive drugs.

Interventions

OTHERChanging dialysate temperature

Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Masking description

Patients, primary providers, ICU nurses and primary nephrology team are blinded. The PI and the dialysis nurses are not.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older, AKI stage 3 requiring RRT, maximum two pressers, initial temperature of 36°C or higher.

Exclusion criteria

* Initial temperature less than 36°C, ESRD, three or more pressers, requirement of antihypertensive medications.

Design outcomes

Primary

MeasureTime frameDescription
Number of intradialytic hypotension episodes with different dialysate temperaturesParticipants who are enrolled are monitored during SLED treatment which can run from 8 to 14 hours for maximum of 8 treatments or till participant is switched to a different dialysis modalityHypothesis is that low dialysate temperature will decrease the number of hypotensive episodes during SLED treatment, hypotensive episodes are defined as drop in SBP ≥ 20 mm Hg or MAP ≥ 10 mm Hg, decrease in ultrafiltration rate, increase or start of vasoactive agents or termination of treatment because of hypotension.

Secondary

MeasureTime frameDescription
Effect on baseline body temperatureParticipants who are enrolled are monitored during SLED treatment which can run from 8 to 14 hours for maximum of 8 treatments or till participant is switched to a different dialysis modalityChange of body temperature during and at end of SLED treatment from baseline temperature measured before starting SLED
Effect on total ultrafiltrationParticipants who are enrolled are monitored during SLED treatment which can run from 8 to 14 hours for maximum of 8 treatments or till participant is switched to a different dialysis modalityThe total amount of fluid ordered to be removed will be compared with the amount actually removed
Effect on Kt/VParticipants who are enrolled are monitored during SLED treatment which can run from 8 to 14 hours for maximum of 8 treatments or till participant is switched to a different dialysis modalityThe dialysis dose will be monitored

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026